![]() |
Cochrane Gynaecological Cancer Review Group |
ChrisWilliams - Co-editing Editor
Anne Oestmann -Trials Search Co-ordinator
Gail Quinn - Review Group Co-ordinator
Clare Jess - Review Group Co-ordinator
CCInfo is an electronic newsletter published by the Canadian Cochrane
Network and Centre on behalf of the Cochrane Collaboration. It is
distributed approximately every two weeks depending on the volume of
news and information.
To subscribe, send an email (from the address you normally use) to:
cochrane@uottawa.ca
The content of your message is simply: subscribe
Don't fill in the subject or add a signature, send it. Free subscription.
The RevMan list serves those using RevMan software to prepare Cochrane systematic reviews. Subscribers are kept up to date with new releases, warned of recently discovered problems, and given the opportunity to seek help from other users and the program developers.
This list has a web interface which is the preferred means of subscribing, unsubscribing, accessing the list archive, and setting options. Note: postings to the list are still delivered to you by email.
RevMan list web page: http://lists.cochrane.org/mailman/listinfo/revman
To send a message to the list, address your email to: revman@lists.cochrane.org
If your message involves a query about RevMan, indicate which version of RevMan you are using.
To subscribe to the list by email rather than using the web page, send an email to
revman-request@lists.cochrane.org
In the body of the message, or in the subject line, put: subscribe
If you want to specify a particular email address, the command is
subscribe address=<email-address>
(fill in your email address, eg: subscribe address=fred@abc.edu)
That's all. Don't fill in the subject or add a signature. Send it.
Requests for technical support from the RevMan team at The Nordic Cochrane Centre should be sent to: revman-techsupport@cochrane.dk
Please remember that this address is for requests that are too specific for discussion on the RevMan email list and require technical knowledge beyond that which could be expected of your Review Group.